Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CapsoVision, Inc. ( (CV) ) has shared an announcement.
On December 29, 2025, CapsoVision, Inc. announced it had submitted a 510(k) application to the U.S. Food and Drug Administration for an AI-assisted reading module for its CapsoCam Plus capsule endoscopy system, a move aimed at improving detection of clinically significant small bowel pathology and reducing clinician review time. The company positions the AI module, supported by an in-house AI capability, a large and growing imaging dataset, and a fully cloud-based architecture, as a differentiator versus competing capsule endoscopy systems, potentially enhancing workflow efficiency, diagnostic accuracy, and accessibility for gastrointestinal practices once regulatory clearance enables U.S. commercialization.
The most recent analyst rating on (CV) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on CapsoVision, Inc. stock, see the CV Stock Forecast page.
Spark’s Take on CV Stock
According to Spark, TipRanks’ AI Analyst, CV is a Neutral.
CapsoVision, Inc. has a mixed outlook. The most significant factor is its poor financial performance, which poses a major risk. However, positive technical indicators and promising corporate events, such as the FDA application and new leadership, provide potential upside. The lack of valuation metrics adds uncertainty to the stock’s assessment.
To see Spark’s full report on CV stock, click here.
More about CapsoVision, Inc.
CapsoVision, Inc. is a commercial-stage medical technology company focused on advanced imaging and AI-enabled capsule endoscopy solutions for the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus, is a wire-free, panoramic capsule endoscope for high-resolution visualization of the small bowel in adults and children from age two, offering cloud-based or direct video retrieval, while its pipeline includes CapsoCam Colon with enhanced AI for non-invasive colon imaging and polyp detection, with plans to expand its proprietary platform across multiple GI indications such as esophageal and pancreatic disorders.
Average Trading Volume: 145,540
Technical Sentiment Signal: Strong Buy
Current Market Cap: $609.4M
For an in-depth examination of CV stock, go to TipRanks’ Overview page.